This report was first published by Endpoints News. To see the original version, click here
Eli Lilly is expanding its collaboration with Innovent Biologics through a new deal featuring a $350 million upfront payment to develop new cancer and immunology drugs.
Their latest partnership marks the seventh deal between the two companies and includes regulatory and commercial milestone payments worth up to $8.5 billion, Innovent announced Sunday.
您已阅读28%（442字），剩余72%（1121字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。